Actionable insights straight to your inbox

Equities logo

Editas Medicine Names Gilmore O’Neill as CEO

O'Neill was most recently chief medical officer at Sarepta Therapeutics.
In the short run, there may be a pause in this tech rally but that's not a given because the longer-term monster move is still there.
Excellent diligence doesn't always mean you'll be saved from a nasty surprise. The nature of investing in biotech means assuming the risk that a therapeutic development program may fail.